Fort Detrick scientist up for Heyman Service to America Medal; Fina Biosolutions to develop and manufacture pneumococcal vax in China;

> Scientists have been carrying out tests of a new universal flu vaccine on elderly members of the population in Winnipeg, Canada, for the past 5 weeks. Story

> Art Friedlander, the Fort Detrick, MD, scientist who improved the anthrax vaccine after 2001 attacks in the U.S., is a Heyman Service to America Medal finalist. News

> Alnylam Pharmaceuticals ($ALNY) announced positive preclinical results in applying its RNAi technology to cancer vaccines. Article

> Fina Biosolutions signed a licensing deal with Chengdu Institute of Biological Products to develop and manufacture a pneumococcal conjugate vaccine in China. Item

> Scientists report new insights into how a family of rare, highly potent antibodies bind to HIV and neutralize it. More

> The European Medicines Agency accepted the filing of Dynavax Technologies' marketing authorization application for the hepatitis B vaccine drug Heplisav. Story

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.